SAREPTA THERAPEUTICS, INC. Increase (Decrease) in Inventories
SAREPTA THERAPEUTICS, INC. (SRPT) reported Increase (Decrease) in Inventories of $29.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was -$39.91M, a 167.43% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $69.76M, a 60.67% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was -$18.48M, a 111.43% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was $83.02M, a 17.69% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2025 was $301.09M, a 23.81% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2024 was $395.17M, a 167.52% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2023 was $147.71M, a 190.89% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2022 was $50.78M, a 39.38% decline from fiscal 2021.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$39.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $29.84M 10-Q · filed 2026-08-05 | $11.37M derived: sum of 3 quarters · filed 2026-08-05 | $94.39M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $69.76M 10-Q · filed 2026-05-06 | $51.28M derived: sum of 2 quarters · filed 2026-05-06 | $134.30M derived: sum of 3 quarters · filed 2026-05-06 | $193.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$18.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $64.55M derived: sum of 2 quarters · filed 2026-03-02 | $123.73M derived: sum of 3 quarters · filed 2026-08-05 | $301.09M 10-K · filed 2026-03-02 |
| 2025-09-30 | $83.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $142.21M derived: sum of 2 quarters · filed 2026-08-05 | $319.57M 10-Q · filed 2025-11-06 | $481.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $59.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $236.55M 10-Q · filed 2026-08-05 | $398.21M derived: sum of 3 quarters · filed 2026-08-05 | $468.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $177.36M 10-Q · filed 2026-05-06 | $339.02M derived: sum of 2 quarters · filed 2026-05-06 | $409.56M derived: sum of 3 quarters · filed 2026-05-06 | $512.02M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $161.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $232.20M derived: sum of 2 quarters · filed 2026-03-02 | $334.66M derived: sum of 3 quarters · filed 2026-03-02 | $395.17M 10-K · filed 2026-03-02 |
| 2024-09-30 | $70.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $173.00M derived: sum of 2 quarters · filed 2025-11-06 | $233.51M 10-Q · filed 2025-11-06 | $327.62M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $102.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $162.97M 10-Q · filed 2025-08-06 | $257.08M derived: sum of 3 quarters · filed 2026-03-02 | $283.69M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $60.51M 10-Q · filed 2025-05-06 | $154.62M derived: sum of 2 quarters · filed 2026-03-02 | $181.23M derived: sum of 3 quarters · filed 2026-03-02 | $207.92M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $94.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $120.72M derived: sum of 2 quarters · filed 2026-03-02 | $147.41M derived: sum of 3 quarters · filed 2026-03-02 | $147.71M 10-K · filed 2026-03-02 |
| 2023-09-30 | $26.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $53.30M derived: sum of 2 quarters · filed 2024-11-06 | $53.61M 10-Q · filed 2024-11-06 | $62.49M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $26.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $27.00M 10-Q · filed 2024-08-07 | $35.88M derived: sum of 3 quarters · filed 2025-02-28 | $62.41M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $306.00K 10-Q · filed 2024-05-01 | $9.19M derived: sum of 2 quarters · filed 2025-02-28 | $35.72M derived: sum of 3 quarters · filed 2025-02-28 | $46.40M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $8.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $35.42M derived: sum of 2 quarters · filed 2025-02-28 | $46.09M derived: sum of 3 quarters · filed 2025-02-28 | $50.78M 10-K · filed 2025-02-28 |
| 2022-09-30 | $26.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $37.21M derived: sum of 2 quarters · filed 2023-11-01 | $41.90M 10-Q · filed 2023-11-01 | $69.16M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $10.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $15.36M 10-Q · filed 2023-08-02 | $42.63M derived: sum of 3 quarters · filed 2024-02-28 | $62.34M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $4.69M 10-Q · filed 2023-05-02 | $31.95M derived: sum of 2 quarters · filed 2024-02-28 | $51.66M derived: sum of 3 quarters · filed 2024-02-28 | $80.09M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $27.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $46.98M derived: sum of 2 quarters · filed 2024-02-28 | $75.40M derived: sum of 3 quarters · filed 2024-02-28 | $83.77M 10-K · filed 2024-02-28 |
| 2021-09-30 | $19.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $48.14M derived: sum of 2 quarters · filed 2022-11-02 | $56.51M 10-Q · filed 2022-11-02 | $68.35M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $28.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $36.80M 10-Q · filed 2022-08-02 | $48.64M derived: sum of 3 quarters · filed 2023-02-28 | $89.11M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $8.37M 10-Q · filed 2022-05-04 | $20.21M derived: sum of 2 quarters · filed 2023-02-28 | $60.68M derived: sum of 3 quarters · filed 2023-02-28 | $67.17M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $11.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $52.31M derived: sum of 2 quarters · filed 2023-02-28 | $58.79M derived: sum of 3 quarters · filed 2023-02-28 | $60.58M 10-K · filed 2023-02-28 |
| 2020-09-30 | $40.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $46.95M derived: sum of 2 quarters · filed 2021-11-03 | $48.74M 10-Q · filed 2021-11-03 | $53.76M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $6.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $8.27M 10-Q · filed 2021-08-04 | $13.29M derived: sum of 3 quarters · filed 2022-03-01 | $23.08M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $1.79M 10-Q · filed 2021-05-05 | $6.81M derived: sum of 2 quarters · filed 2022-03-01 | $16.60M derived: sum of 3 quarters · filed 2022-03-01 | $32.70M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $5.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $14.81M derived: sum of 2 quarters · filed 2022-03-01 | $30.91M derived: sum of 3 quarters · filed 2022-03-01 | $45.93M 10-K · filed 2022-03-01 |
| 2019-09-30 | $9.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $25.89M derived: sum of 2 quarters · filed 2020-11-05 | $40.91M 10-Q · filed 2020-11-05 | $50.54M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $16.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $31.12M 10-Q · filed 2020-08-05 | $40.75M derived: sum of 3 quarters · filed 2021-03-01 | $52.44M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $15.02M 10-Q · filed 2020-05-06 | $24.65M derived: sum of 2 quarters · filed 2021-03-01 | $36.34M derived: sum of 3 quarters · filed 2021-03-01 | $41.09M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $9.63M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $21.32M derived: sum of 2 quarters · filed 2021-03-01 | $26.07M derived: sum of 3 quarters · filed 2021-03-01 | $41.84M 10-K · filed 2021-03-01 |
| 2018-09-30 | $11.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $16.44M derived: sum of 2 quarters · filed 2019-11-07 | $32.21M 10-Q · filed 2019-11-07 | $51.12M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $4.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $20.52M 10-Q · filed 2019-08-07 | $39.43M derived: sum of 3 quarters · filed 2020-02-26 | $62.37M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $15.77M 10-Q · filed 2019-05-08 | $34.68M derived: sum of 2 quarters · filed 2020-02-26 | $57.62M derived: sum of 3 quarters · filed 2020-02-26 | $68.93M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $18.91M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $41.85M derived: sum of 2 quarters · filed 2020-02-26 | $53.16M derived: sum of 3 quarters · filed 2020-02-26 | $70.79M 10-K · filed 2020-02-26 |
| 2017-09-30 | $22.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $34.25M derived: sum of 2 quarters · filed 2018-10-31 | $51.88M 10-Q · filed 2018-10-31 | $61.77M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $11.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $28.94M 10-Q · filed 2018-08-08 | $38.83M derived: sum of 3 quarters · filed 2019-02-28 | |
| 2017-03-31 | $17.63M 10-Q · filed 2018-05-03 | $27.52M derived: sum of 2 quarters · filed 2019-02-28 | ||
| 2016-12-31 | $9.89M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $12.81M 10-K · filed 2019-02-28 | ||
| 2016-09-30 | $2.92M 10-Q · filed 2017-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |